Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 387Observational 13Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Solid Tumors 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

abemaciclib 2Alpelisib 2zenocutuzumab 1tucatinib 1selpercatinib 1ribociclib 1pegilodecakin 1iniparib 1eribulin 1Proton Pump Inhibitors 1Lapatinib 1Hydrocortisone 1Everolimus 1Capecitabine 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Breast Neoplasms × Capecitabine × Clear all
NCT00338247 2016-04-06

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Novartis

Approved for marketing
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡